VXM01

BIOLOGICAL4 trials

Sponsors

Vaximm GmbH

Conditions

Colorectal CancerGlioblastomaRecurrent GlioblastomaStage IV Pancreatic Cancer

Phase 1

VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer

CompletedNCT01486329

Vaximm GmbHStage IV Pancreatic Cancer

Start: 2011-12-31End: 2014-12-31Updated: 2015-06-08

VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis

CompletedNCT02718430

Vaximm GmbHColorectal Cancer

Start: 2016-02-29End: 2018-03-31Updated: 2018-10-19

VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma

CompletedNCT02718443

Vaximm GmbHGlioblastoma

Start: 2016-05-31End: 2018-07-31Updated: 2018-10-19

VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma

Vaximm GmbHRecurrent Glioblastoma

Start: 2018-11-21End: 2022-12-31Target: 30Updated: 2022-10-20

Related Papers

AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas

Neurological Research and Practice2022-05-2337 citations

Oral DNA vaccination targeting VEGFR2 combined with anti-PDL1 avelumab in patients with progressive glioblastoma: Safety run-in results—NCT03750071.

Journal of Clinical Oncology2020-05-207 citations

Oral DNA vaccination targeting VEGFR-2 combined with anti-PD-L1 avelumab in patients with progressive glioblastoma, a phase I/II study: NCT03750071.

Journal of Clinical Oncology2019-05-20

VXM01 phase I study in patients with progressive glioblastoma: Final results.

Journal of Clinical Oncology2018-05-2016 citations

VXM01 phase I study in patients with resectable progression of a glioblastoma.

Journal of Clinical Oncology2017-05-204 citations

Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer.

2012-08-2045 citations